Objective: The objective of this study was to analyze the available literature on using transcatheter aortic valve replacement (TAVR) for native aortic regurgitation (AR).
treatment for intermediate, high risk, and prohibitive risk patients with symptomatic aortic stenosis [3] [4] [5] . With the expansion of indications for TAVR in severe aortic stenosis, avenues for use other than aortic valve stenosis have also been explored. These include TAVR in bicuspid aortic valve stenosis, surgical prosthesis degeneration, and some instances of tricuspid, mitral, and pulmonic valve disease [6] [7] [8] .
Among these novel uses, TAVR for pure native AR comes with its own set of unique challenges and limitations. The absence of calcification in the aortic annulus results in lack of proper anchoring, predisposing to valve embolization 9 . Associated dilatation of the aortic root often results in annular dimensions, which exceed currently available commercial percutaneous valve technologies. Furthermore, hypercontractility of the left ventricle (LV) and augmentation of the stroke volume due to increased LV end-diastolic volume can make precise valve positioning challenging 10 . Despite these limitations, several reports of TAVR in pure native AR have emerged in recent years. These studies vary considerably in methodological and patient characteristics, and most have small sample sizes, which makes it difficult to interpret the results.
We aimed to meta-analyze the results of these studies and account for several study level covariates to provide an estimate of the safety and efficacy of TAVR in pure native valve AR.
| MATERIALS AND METHODS
This meta-analysis conforms to the guidelines set by PRISMA (Preferred Reporting Items for Systematic review and Meta-Analyses) and AHA (American Heart Association) guidelines 11, 12 .
| Literature search
The following databases were searched for relevant studies from their date of inception until March 2008: MEDLINE, Scopus, and Cochrane CENTRAL. The search strategy used in each database is given in Supporting Information Table S1 . Snowballing from relevant systematic reviews was also performed to ensure no pertinent article was overlooked. All retrieved articles were transferred to Endnote X7
(Clarivate Analytics, PA), and duplicates were identified and removed.
Two reviewers (WFR and MSU) independently evaluated the remaining articles for relevance. Initial screening was done on the basis of titles and abstracts, following which the full-text was scrutinized. Any discrepancies between the two reviewers were solved by discussion until consensus was reached.
| Study selection
Studies were eligible for inclusion if they met the following prespecified criteria: (1) Were published full texts or abstracts in the English language; (2) Included patients with pure native valve AR undergoing TAVR; (3) Included at least five patients; and (4) Reported at least one of the prespecified endpoints to be included in the meta-analysis.
Case reports and editorials were excluded. In case of serial publications, only the most recent one was included. was used to assess heterogeneity and a value of I 2 = 25%-50% was considered mild, 50%-75% as moderate, and > 75% as severe 16 . A Pvalue of <0.05 was considered significant in all cases.
| Data extraction
3 | RESULTS
| Literature search and study characteristics
The initial search revealed a total of 5,208 potential articles. After exclusions, 19 reports remained for analysis (13 full texts [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , and 6 conference abstracts [30] [31] [32] [33] [34] [35] ). The PRISMA flow chart ( Figure 1 ) gives an overview of the literature search. The 19 studies included a total of 998 patients undergoing TAVR for pure native AR. Eleven studies had a multicenter design while the remaining eight were single-center.
The mean age of the patients ranged from 68 to 84 years, and the mean logistic EUROSCORE ranged from 9.8 to 34.0. Relevant study, patient, and procedural characteristics are displayed in Table 1 . For the purpose of this meta-analysis, no sex-based or race/ethnicitybased differences were present.
| Results of meta-analysis
Results of the meta-analysis are summarized in Figure 2 . Detailed forest plots outlining the effect size of each study are given in the online supplementary material (Supporting Information Figures S1-S6). Figure S1 )
| Thirty-day mortality (Supporting Information
The 30-day mortality was reported in all studies, and ranged from 0% Meta regression revealed no significant association between 30-day mortality rate, and the mean age (P = 0.40), mean annulus size (P = 0.88), proportion of patients with moderate-severe baseline MR (P = 0.87), or mean logistic EUROSCORE (P = 0.98). Figure S2 ) Meta regression showed no significant association between device success and mean age (P = 0.98), mean annulus size (P = 0.81),
| Device success (Supporting Information
proportion of patients with moderate-severe baseline MR (P = 0.51), or logistic EUROSCORE (P = 0.44). Figure S3 )
| PPM implantation (Supporting Information
Fourteen studies reported the rate of post-procedural PPM implantation. This varied from 0% to 44%, with a pooled estimate of 13.1%
(9.3%-17.5%; I 2 = 44%). There was no significant difference (P = 0.09) in the rate of PPM implantation between the studies using new generation valves [10.4% (6.6%-15.0%); I 2 = 15%], and the Meta-regression revealed a significant positive association between average age and rate of PPM implantation after the procedure (P < 0.001). Rate of PPM implantation was not associated with mean annulus size (P = 0.55), proportion of patients with moderatesevere MR (P = 0.89), or logistic EUROSCORE (P = 0.72). Figure S4) Eleven studies reported the incidence of post TAVR major bleeding, which ranged from 0% to 15%. Upon pooling all studies, the occurrence of major bleeding was estimated as 12.4% [6.1%-20.4% (I 2 = 82%)]. Figure S5 )
| Major bleeding (Supporting Information

| Residual moderate to severe AR (Supporting Information
The rate of post-TAVR residual moderate-severe AR was reported by 18 studies. The occurrence of residual moderate to severe AR varied from 0% to 29% with a pooled estimate of 9.2% (5.5%-13.7%; Meta-regression revealed that moderate-severe AR was not associated with average age (P = 0.53), mean annulus size (P = 0.28),
proportion of patients with moderate-severe MR (P = 0.76), or logistic EUROSCORE (P = 0.97).
| Cardiovascular outcomes
Eleven studies had myocardial infarction as an outcome, and all reported no cases at 30 days. Among the 13 studies reporting stroke, its occurrence ranged from 0% to 6%, with a pooled estimate of 3.6%
[2.3%-5.1%; (I 2 = 0%)] (Supporting Information Figure S6 ). Figure s7) Six studies reported the incidence of one-year mortality, which varied from 20% to 31%, with a pooled incidence of 24.7% [21.3%-28.1%; (I 2 = 0%)]. 
| One-year mortality (Supporting Information
| DISCUSSION
The main findings of this systematic review and meta-analysis reveal that (1) TAVR is a viable option for carefully selected patients with pure AR with acceptable associated device success, procedural safety, and morbidity; (2) Newer generation transcatheter heart valves showed excellent outcomes that were significantly superior to older devices. To the best of our knowledge, this systematic review and meta-analysis on pure native AR has the largest number of patients to date. There is an unmet clinical need in the management of severe symptomatic AR 36 . Although purpose-specific devices have been used in this setting, it is unlikely that these valves will be widely developed and utilized for this purpose alone given the modest size of the market. Hence, non-purpose-specific valves have been used off-label for severe AR and their outcomes have been promising, especially with newer generation valves as evident by our meta-analysis.
Our results show that the one-year mortality after TAVR for pure moderate to severe native AR is~25%. Albeit high, this mortality rate . This procedure results in lower long-term mortality, immediate, and sustainable symptomatic improvement even for patients with advanced disease and left ventricular dysfunction 9, 38 .
The advancement of device technology, improvement in operator expertise, and better TAVR outcomes overall have opened up a new approach to AR [39] [40] [41] [42] . Device success, as judged by the VARC-2 criteria, was also better when newer generation devices were used.
However, using TAVR for the treatment of pure native AR can be challenging due to anatomic and clinical differences compared with aortic stenosis, and is therefore currently not indicated in patients with predominant AR in the current guidelines 43, 44 . The largest cohort included in this review by Yoon et al. showed that compared with first-generation devices, second-generation devices had significantly less residual AR 18 . This was attributable to the newer generation devices having an external cuff to seal off the aortic annulus at the time of implantation, better recapture, and repositioning ability, and a distinct mechanism to anchor the valve. In line with our metaanalysis, this study by Yoon et al. also showed that the device success rate according to VARC-2 criteria was significantly higher in newer generation devices compared with the first generation ones 18 .
| Limitations
Although this systemic review tried to include all the studies that fell within the inclusion criteria, the number of studies included was modest. The literature lacks a prospective randomized study examining the outcomes of TAVR in pure native AR, which limits the extrapolation of the results of all the observational studies done. Moreover, there was significant heterogeneity across the available studies in terms of device used, access site, and outcome reporting, which makes it impossible to have homogenous result reporting. This is further limited by the fact that some studies have incomplete data reporting. Most of the studies reported their outcomes periprocedurally and lack long-term outcome data, which is critical if this therapeutic approach needs to gain a larger role for treatment of pure native AR.
| CONCLUSIONS
Despite SAVR being the treatment of choice for AR, TAVR has shown promising results and favorable feasibility in early reports with comparable short-term outcomes. There remains a need for prospective study with long-term data to evaluate the use of TAVR for pure native AR. This also needs to be coupled with further development and modification of TAVR prostheses to address the procedural challenges of using TAVR in pure native AR, and the development of dedicated prostheses for AR.
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Additional supporting information may be found online in the Supporting Information section at the end of the article. 
